| On-demand preexposure prophylaxis in men at high risk for HIV-1 infection JM Molina, C Capitant, B Spire, G Pialoux, L Cotte, I Charreau, ... New England Journal of Medicine 373 (23), 2237-2246, 2015 | 1882 | 2015 |
| Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment L Ferradini, A Jeannin, L Pinoges, J Izopet, D Odhiambo, L Mankhambo, ... The lancet 367 (9519), 1335-1342, 2006 | 595 | 2006 |
| Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study JM Molina, I Charreau, B Spire, L Cotte, J Chas, C Capitant, C Tremblay, ... The lancet HIV 4 (9), e402-e410, 2017 | 502 | 2017 |
| International AIDS Society global scientific strategy: towards an HIV cure 2016 SG Deeks, SR Lewin, AL Ross, J Ananworanich, M Benkirane, P Cannon, ... Nature medicine 22 (8), 839-850, 2016 | 495 | 2016 |
| Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach B Spire, S Duran, M Souville, C Leport, F Raffi, JP Moatti Social science & medicine 54 (10), 1481-1496, 2002 | 454 | 2002 |
| Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light B Spire, F Barre-Sinoussi, D Dormont, L Montagnier, JC Chermann The Lancet 325 (8422), 188-189, 1985 | 443 | 1985 |
| Inactivation of lymphadenopathy associated virus by chemical disinfectants B Spire, L Montagnier, F Barre-Sinoussi, JC Chermann The Lancet 324 (8408), 899-901, 1984 | 375 | 1984 |
| Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission LG Bekker, G Alleyne, S Baral, J Cepeda, D Daskalakis, D Dowdy, ... The Lancet 392 (10144), 312-358, 2018 | 370 | 2018 |
| Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy S Duran, M Savès, B Spire, V Cailleton, A Sobel, P Carrieri, D Salmon, ... Aids 15 (18), 2441-2444, 2001 | 359 | 2001 |
| Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial JM Molina, I Charreau, C Chidiac, G Pialoux, E Cua, C Delaugerre, ... The Lancet Infectious Diseases 18 (3), 308-317, 2018 | 335 | 2018 |
| Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment JP Moatti, MP Carrieri, B Spire, JA Gastaut, JP Cassuto, J Moreau, ... Aids 14 (2), 151-155, 2000 | 320 | 2000 |
| Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART S Duran, B Spire, F Raffi, V Walter, D Bouhour, V Journot, V Cailleton, ... HIV clinical trials 2 (1), 38-45, 2001 | 311 | 2001 |
| On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial JM Molina, C Capitant, B Spire, G Pialoux, C Chidiac, I Charreau, ... Conference on retroviruses and opportunistic infections 2015, 2015 | 263 | 2015 |
| Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial CC Iwuji, J Orne-Gliemann, J Larmarange, E Balestre, R Thiebaut, ... The lancet HIV 5 (3), e116-e125, 2018 | 253 | 2018 |
| Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. W Rozenbaum, D Dormont, B Spire | 246 | 1985 |
| Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme M BouHamdan, S Benichou, F Rey, JM Navarro, I Agostini, B Spire, ... Journal of virology 70 (2), 697-704, 1996 | 245 | 1996 |
| The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort P Carrieri, V Cailleton, V Le Moing, B Spire, P Dellamonica, E Bouvet, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 28 (3), 232-239, 2001 | 244 | 2001 |
| Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy MANIF 2000 Study Group Antiviral Therapy 10 (1), 53-61, 2005 | 225 | 2005 |
| Characterization of the RNA dependent DNA polymerase of a new human T lymphotropic retrovirus (lymphadenopathy associated virus) MA Rey, B Spire, D Dormont, F Barré-Sinoussi, L Montagnier, ... Biochemical and Biophysical Research Communications 121 (1), 126-133, 1984 | 202 | 1984 |
| Health-related quality of life after 1 year of highly active antiretroviral therapy P Carrieri, B Spire, S Duran, C Katlama, D Peyramond, C François, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 32 (1), 38-47, 2003 | 199 | 2003 |
